AstraZeneca Makes Smart Move With Summit Therapeutics Deal — Market Talk
AstraZeneca's deal with Summit Therapeutics looks like a strategically smart move for the U.K. drugmaker, which adds combination options for its portfolio while keeping risk exposure low, analysts at Jefferies say in a research note. AstraZeneca is taking a 12% stake in Summit for $2 billion and en…